FDA Approves Enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC)

The U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). Enzalutamide was previously approved only for patients with metastatic CRPC. Prior to this past February – when the FDA also approved apalutamide (Erleada) for non-metastatic CRPC – there were no FDA-approved treatments for these men.

Read more on PCF.org HERE

A Generic Version of Zytiga Has Been Approved by the FDA

It has just been recently announced that the U.S. Food and Drug Administration (FDA) has approved a generic version of Zytiga, the new drug’s name is Yonsa.  It is a novel formulation of abiraterone acetate that needs to be used in combination with methylprednisolone for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

Read the complete article on CancerABCs.org HERE

LuPSMA treatment (Lutetium-177 PSMA-617)​

An exciting proof-of-concept study of Lutetium-177 PSMA (Lu PSMA) was published in the journal Lancet Oncology. Lu-PSMA has been described as “a disruptive therapy and has the potential to change practice” in the future treatment of men with end-stage prostate cancer.

Lu-PSMA, a nuclear therapy, has been used in Germany for many years under compassionate use basis.  This particular study was conducted in Australia. The study results offer hope for men with end-stage prostate cancer who have exhausted all their treatment options.

Read more on Prostate Cancer Foundation HERE
and CancerABCs.org HERE
and SBS News HERE

Research finds ‘Achilles heel’ for aggressive prostate cancer. Drug makes prostate cancer cells self destruct

UC San Francisco researchers have discovered a promising new line of attack against lethal, treatment-resistant prostate cancer. Analysis of hundreds of human prostate tumors revealed that the most aggressive cancers depend on a built-in cellular stress response to put a brake on their own hot-wired physiology. Experiments in mice and with human cells showed that blocking this stress response with an experimental drug—previously shown to enhance cognition and restore memory after brain damage in rodents—causes treatment-resistant cancer cells to self-destruct while leaving normal cells unaffected.​

The new study was published online May 2, 2018 in Science Translational Medicine.​

Read the entire article on MedicalXpress.com HERE
and technologyneworks.com HERE

Sequencing and Combining CRPC Therapies – What Does the Future Hold?

Since 2010, many new agents have joined our armamentarium for treating metastatic CRPC, raising the question of how best to sequence them. For men with newly diagnosed, presumably hormone-sensitive mPC, we usually start treatment with either abiraterone acetate or docetaxel. Therefore, although we have five or six approved treatments for mCRPC, not every patient should receive all of them.

Click here to read more…….

FDA approves apalutamide (Erleada) for the treatment of non-metastatic castration-resistant prostate cancer

February 14, 2018 – Today the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada, also previously called ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (non-metastatic CRPC). This clinical setting is when men who are being treated with Androgen deprivation therapy (ADT) see their PSA levels begin to rise, but no metastases are visible yet on scans. There were previously no FDA-approved treatments for non-metastatic CRPC, and patients typically continued to receive ADT, despite its diminishing benefit.

To read more about this, click HERE.

Experts Discuss Emerging Targets, Diagnostics, Therapies in Advanced Prostate Cancer

From the 2018 Genitourinary Cancers Symposium:

Diagnosis and treatment of advanced prostate cancer continue to evolve. A better understanding of the genomics of this malignancy, as well as improved imaging techniques and developments of new therapeutics, are pushing that evolution. Several experts discussed the changing field of advanced prostate cancer management on February 8.

Read more here